{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T04:16:09Z","timestamp":1787026569908,"version":"build-2736575974"},"reference-count":46,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,9,17]],"date-time":"2025-09-17T00:00:00Z","timestamp":1758067200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82103318"],"award-info":[{"award-number":["82103318"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>While immunotherapy has redefined clinical paradigms for advanced gastric cancer, reliable efficacy prediction remains a critical unmet challenge. Unlike invasive tissue-based predictors, circulating biomarkers offer non-invasive monitoring potential. This study investigated serum energy metabolites, whose dysregulation drove immune evasion, as predictors of therapeutic efficacy in advanced gastric cancer receiving first-line chemoimmunotherapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted a prospective observational study involving 52 patients with advanced gastric cancer receiving first-line chemoimmunotherapy. Serum metabolites of glycolysis and tricarboxylic acid (TCA) cycle were quantified via high-performance liquid chromatography-tandem mass spectrometry. Therapeutic response, progression-free survival (PFS), and overall survival (OS) were served as evaluation endpoints.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Patients exhibiting decreased serum concentrations of glycolytic metabolites (lactate and pyruvate) demonstrated significantly higher disease control rate (DCR) compared to those with elevated concentrations. Elevated serum lactate and pyruvate were significantly associated with inferior PFS and OS. Multivariate Cox regression established low lactate and pyruvate as independent prognostic factors for improved PFS and OS. However, no significant associations were observed between serum TCA cycle metabolites (citrate, isocitrate, \u03b1-ketoglutarate, succinate, fumarate, malate, and oxaloacetate) and DCR, PFS, or OS.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Our findings suggest that serum lactate and pyruvate as non-invasive glycolytic biomarkers with substantial predictive value for immunotherapy efficacy in advanced gastric cancer, requiring validation in larger cohorts to guide therapeutic decisions.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2025.1663362","type":"journal-article","created":{"date-parts":[[2025,9,17]],"date-time":"2025-09-17T05:40:31Z","timestamp":1758087631000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["Serum pyruvate and lactate predict immunotherapy efficacy in advanced gastric cancer: a prospective biomarker study"],"prefix":"10.3389","volume":"16","author":[{"given":"Chang","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Dai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiru","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingjing","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bin","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,9,17]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21834","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(25)00052-2","article-title":"Gastric cancer","volume":"405","author":"Sundar","year":"2025","journal-title":"Lancet"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.5230\/jgc.2025.25.e10","article-title":"A comprehensive and comparative review of global gastric cancer treatment guidelines: 2024 update","volume":"25","author":"Eom","year":"2025","journal-title":"J Gastric Cancer"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1599908","article-title":"Predictive biomarkers in the era of immunotherapy for gastric cancer: current achievements and future perspectives","volume":"16","author":"Sun","year":"2025","journal-title":"Front Immunol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1007\/s00432-022-04408-0","article-title":"Predictive biomarkers in gastric cancer","volume":"149","author":"R\u00f6cken","year":"2023","journal-title":"J Cancer Res Clin Oncol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-023-01715-z","article-title":"Clinical application and detection techniques of liquid biopsy in gastric cancer","volume":"22","author":"Ma","year":"2023","journal-title":"Mol Cancer"},{"key":"B7","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.cytogfr.2022.11.001","article-title":"Crosstalk between glucose metabolism, lactate production and immune response modulation","volume":"68","author":"Ye","year":"2022","journal-title":"Cytokine Growth Factor Rev"},{"key":"B8","doi-asserted-by":"publisher","first-page":"116030","DOI":"10.1016\/j.biopha.2023.116030","article-title":"Effect of metabolic reprogramming on the immune microenvironment in gastric cancer","volume":"170","author":"Shang","year":"2024","journal-title":"BioMed Pharmacother"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.molcel.2020.04.002","article-title":"Cytokine-like roles for metabolites in immunity","volume":"78","author":"Zas\u0142ona","year":"2020","journal-title":"Mol Cell"},{"key":"B10","doi-asserted-by":"publisher","first-page":"217156","DOI":"10.1016\/j.canlet.2024.217156","article-title":"Glycolysis, the sweet appetite of the tumor microenvironment","volume":"600","author":"Kooshan","year":"2024","journal-title":"Cancer Lett"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23105572","article-title":"Targeting energy metabolism in cancer treatment","volume":"23","author":"Kubik","year":"2022","journal-title":"Int J Mol Sci"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbadis.2024.167120","article-title":"Multi-OMICS approaches in cancer biology: New era in cancer therapy","volume":"1870","author":"Chakraborty","year":"2024","journal-title":"Biochim Biophys Acta Mol Basis Dis"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25063563","article-title":"Immunotherapy and cancer: the multi-omics perspective","volume":"25","author":"Donisi","year":"2024","journal-title":"Int J Mol Sci"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(23)00515-6","article-title":"Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trial","volume":"24","author":"Rha","year":"2023","journal-title":"Lancet Oncol"},{"key":"B15","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/S0140-6736(21)00797-2","article-title":"First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial","volume":"398","author":"Janjigian","year":"2021","journal-title":"Lancet"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(21)00692-6","article-title":"Nivolumab plus chemotherapy versus placebo plus chemotherapy in patients with HER2-negative, untreated, unresectable advanced or recurrent gastric or gastro-oesophageal junction cancer (ATTRACTION-4): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial","volume":"23","author":"Kang","year":"2022","journal-title":"Lancet Oncol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2023.19918","article-title":"Sintilimab plus chemotherapy for unresectable gastric or gastroesophageal junction cancer: the ORIENT-16 randomized clinical trial","volume":"330","author":"Xu","year":"2023","journal-title":"JAMA"},{"key":"B18","doi-asserted-by":"publisher","first-page":"e078876","DOI":"10.1136\/bmj-2023-078876","article-title":"Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first line treatment for advanced gastric or gastro-oesophageal junction adenocarcinoma: RATIONALE-305 randomised, double blind, phase 3 trial","volume":"385","author":"Qiu","year":"2024","journal-title":"BMJ"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2023.01.009","article-title":"Metabolic programming and immune suppression in the tumor microenvironment","volume":"41","author":"Arner","year":"2023","journal-title":"Cancer Cell"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1172\/JCI72873","article-title":"Pyruvate carboxylase is critical for non-small-cell lung cancer proliferation","volume":"125","author":"Sellers","year":"2015","journal-title":"J Clin Invest"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-07-035972","article-title":"Inhibitory effect of tumor cell-derived lactic acid on human T cells","volume":"109","author":"Fischer","year":"2007","journal-title":"Blood"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-05-1795","article-title":"Tumor-derived lactic acid modulates dendritic cell activation and antigen expression","volume":"107","author":"Gottfried","year":"2006","journal-title":"Blood"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.8623","article-title":"Human mesenchymal stromal cell-secreted lactate induces M2-macrophage differentiation by metabolic reprogramming","volume":"7","author":"Selleri","year":"2016","journal-title":"Oncotarget"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmet.2016.08.011","article-title":"LDHA-associated lactic acid production blunts tumor immunosurveillance by T and NK cells","volume":"24","author":"Brand","year":"2016","journal-title":"Cell Metab"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1038\/ni.3577","article-title":"Foxp3 and Toll-like receptor signaling balance T(reg) cell anabolic metabolism for suppression","volume":"17","author":"Gerriets","year":"2016","journal-title":"Nat Immunol"},{"key":"B26","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1007\/s10142-023-01155-4","article-title":"Glycolysis induces Th2 cell infiltration and significantly affects prognosis and immunotherapy response to lung adenocarcinoma","volume":"23","author":"Zeng","year":"2023","journal-title":"Funct Integr Genomics"},{"key":"B27","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1186\/s12885-024-12747-z","article-title":"Glycolysis-related genes predict prognosis and indicate immune microenvironment features in gastric cancer","volume":"24","author":"Xu","year":"2024","journal-title":"BMC Cancer"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-022-11502-7","article-title":"Glycolysis-related gene signature can predict survival and immune status of hepatocellular carcinoma","volume":"29","author":"Xu","year":"2022","journal-title":"Ann Surg Oncol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1430583","article-title":"Development and validation of a glycolysis-associated gene signature for predicting the prognosis, immune landscape, and drug sensitivity in bladder cancer","volume":"15","author":"Shen","year":"2024","journal-title":"Front Immunol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2021.684322","article-title":"Comprehensive analysis of glycolysis-related genes for prognosis, immune features, and candidate drug development in colon cancer","volume":"9","author":"Cui","year":"2021","journal-title":"Front Cell Dev Biol"},{"key":"B31","doi-asserted-by":"publisher","first-page":"3574","DOI":"10.3390\/cancers12123574","article-title":"Metabolomics to assess response to immune checkpoint inhibitors in patients with non-small-cell lung cancer","volume":"12","author":"Ghini","year":"2020","journal-title":"Cancers (Basel)"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.1025046","article-title":"Metabolomics profiling in prediction of chemo-immunotherapy efficiency in advanced non-small cell lung cancer","volume":"12","author":"Mei","year":"2022","journal-title":"Front Oncol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1016\/j.molcel.2016.02.011","article-title":"Mitochondria and cancer","volume":"61","author":"Zong","year":"2016","journal-title":"Mol Cell"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1038\/s41388-020-01639-8","article-title":"The functional roles of TCA cycle metabolites in cancer","volume":"40","author":"Eniafe","year":"2021","journal-title":"Oncogene"},{"key":"B35","doi-asserted-by":"publisher","first-page":"3177","DOI":"10.1038\/s41467-025-58429-7","article-title":"Cholangiocarcinoma PDHA1 succinylation suppresses macrophage antigen presentation via alpha-ketoglutaric acid accumulation","volume":"16","author":"Zhang","year":"2025","journal-title":"Nat Commun"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1021\/acsbiomaterials.4c01702","article-title":"\u03b1-ketoglutaric acid reprograms macrophages by altering energy metabolism to promote the regeneration of small-diameter vascular grafts","volume":"11","author":"Li","year":"2025","journal-title":"ACS Biomater Sci Eng"},{"key":"B37","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1016\/j.chom.2023.04.010","article-title":"Fusobacterium nucleatum-derived succinic acid induces tumor resistance to immunotherapy in colorectal cancer","volume":"31","author":"Jiang","year":"2023","journal-title":"Cell Host Microbe"},{"key":"B38","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/j.molcel.2019.10.023","article-title":"Cancer-derived succinate promotes macrophage polarization and cancer metastasis via succinate receptor","volume":"77","author":"Wu","year":"2020","journal-title":"Mol Cell"},{"key":"B39","doi-asserted-by":"publisher","first-page":"111193","DOI":"10.1016\/j.celrep.2022.111193","article-title":"Succinate uptake by T cells suppresses their effector function via inhibition of mitochondrial glucose oxidation","volume":"40","author":"Gudgeon","year":"2022","journal-title":"Cell Rep"},{"key":"B40","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1016\/j.cmet.2023.04.017","article-title":"Cancer-cell-derived fumarate suppresses the anti-tumor capacity of CD8+ T cells in the tumor microenvironment","volume":"35","author":"Cheng","year":"2023","journal-title":"Cell Metab"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1016\/j.tem.2025.03.008","article-title":"Fumarate integrates metabolism and immunity in diseases","author":"Cheng","year":"2025","journal-title":"Trends Endocrinol Metab"},{"key":"B42","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.bbcan.2017.01.002","article-title":"Cancer cell metabolism and mitochondria: Nutrient plasticity for TCA cycle fueling","volume":"1868","author":"Corbet","year":"2017","journal-title":"Biochim Biophys Acta Rev Cancer"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.3892\/or.2020.7643","article-title":"Mechanistic insight of predictive biomarkers for antitumor PD\u22121\/PD\u2212L1 blockade: A paradigm shift towards immunome evaluation (Review)","volume":"44","author":"You","year":"2020","journal-title":"Oncol Rep"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2022.e10899","article-title":"Biomarkers of gastric cancer: current advancement","volume":"8","author":"Jiang","year":"2022","journal-title":"Heliyon"},{"key":"B45","doi-asserted-by":"publisher","first-page":"eaaw5473","DOI":"10.1126\/science.aaw5473","article-title":"Metabolic reprogramming and cancer progression","volume":"368","author":"Faubert","year":"2020","journal-title":"Science"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1093\/clinchem\/hvad176","article-title":"Extracellular vesicles as liquid biopsy biomarkers across the cancer journey: from early detection to recurrence","volume":"70","author":"Rayamajhi","year":"2024","journal-title":"Clin Chem"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1663362\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,17]],"date-time":"2025-09-17T05:40:33Z","timestamp":1758087633000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1663362\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,17]]},"references-count":46,"alternative-id":["10.3389\/fimmu.2025.1663362"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1663362","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,17]]},"article-number":"1663362"}}